For the first time since last July the FDA's Oncologic Drugs Advisory Committee (ODAC) will meet on Thursday to evaluate two ...

Prostate cancer represents one of the most common malignancies in men in developed countries with increasing incidence in recent years due to the ...

Patients with benign prostatic hyperplasia (BPH) with preoperative overactive bladder (OAB) have higher postoperative storage ...

The National Comprehensive Cancer Network® (NCCN®)-an alliance of leading cancer centers-has published a new book explaining ...

Researchers at the University of British Columbia and BC Cancer have developed a new way to target proteins long considered ...

Nuclear medicine is being called a new frontier in cancer care, and new research shows potential new uses for it in treating ...

Investigators proposed criteria to define procedural success after minimally invasive surgical treatments (MISTs) for benign prostatic obstruction (BPO).

Jyong Biotech Ltd. (Nasdaq: MENS) (the “Company” or “Jyong Biotech”), a science-driven biotechnology company dedicated to the development and commercialization of innovative plant-derived therapeutics ...

Breakthroughs in identifying tumor biomarkers in liver, gastric, prostate, lung and other cancers and are accelerating ...

But our latest research shows that prostate cancer overdiagnosis from PSA screening is mainly a risk for men over the age of ...

Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the "Company"), a biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutics ...

Researchers at the University of British Columbia and BC Cancer have developed a new way to target proteins long considered ...